Recurrent Aphthous Stomatitis: Treatment and Management

Marco Manfredini¹, Stefania Guida¹, Matteo Giovani¹, Nicola Lippolis¹, Enrico Spinas², Francesca Farnetani¹, Annunziata Dattola³, Eleonora Di Matteo³, Giovanni Pellacani³, Luca Giannetti⁵

1 Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
2 Department of Surgical Sciences, University of Cagliari, Cagliari, Italy
3 Dermatology Clinic, Department of Systems Medicine, Tor Vergata University, Rome, Italy
4 Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
5 Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dental Unit, University of Modena and Reggio Emilia, Modena, Italy

Key words: oral, aphthae, recurrent, autoimmune, treatment, herpetiform, aphthosis, Behçet disease

Citation: Manfredini M, Guida S, Giovani M, Lippolis N, Spinas E, Farnetani F, Dattola A, Di Matteo E, Pellacani G, Giannetti L. Recurrent aphthous stomatitis: treatment and management. Dermatol Pract Concept. 2021;11(4):e2021099. DOI: https://doi.org/10.5826/dpc.1104a99

Accepted: February 28, 2021; Published: September, 2021

Copyright: ©2021 Manfredini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: The authors have no conflicts of interest to disclose.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Marco Manfredini, MD, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Via Università, 4, Modena, Italy. Email: manfredini07@gmail.com

ABSTRACT

Background: Recurrent aphthous stomatitis consists of the presence of abrasions or ulcerations located on mucosa (oral or genital).

Objectives: The aim of this article is to review the current literature providing the main causes related to recurrent aphthous stomatitis and insights into treatment and management of this clinical condition

Methods: Articles matching terms that correlated with “recurrent aphthous stomatitis” were searched on PubMed, EMBASE, and Cochrane Library and selected according to their pertinence.

Results: Several forms of aphthous stomatitis have been described, based on the extent (minor, major), morphology (herpetiform) and associations to other signs (Behçet syndrome or more complex inflammatory syndromes). Topical as well as systemic treatments have been described to obtain a faster remission of the aphthosis or to reduce associated symptoms such as pain.

Conclusions: Recurrent aphthous stomatitis can have a mild-to-severe clinical appearance, being mainly localized on the oral mucosa or at the level of the genital area. Different strategies have been described so far for its management and treatment.
Introduction

Aphtha is defined as a round abrasion or ulceration of oral (or genital) mucosa with a 2- to 5-mm diameter [1]. Lesions are usually covered by a fibrinous pseudomembrane, may be single or multiple, and usually resolve in 10-15 days, but generally recur. Lesions are painful and are often exacerbated by food intake [1]. A specific etiologic factor has not been identified yet.

There are at least 5 forms of aphthosis [1,2]:
1. Recurrent aphthosis minor
2. Recurrent aphthosis ulcer minor (Mikulicz ulcer)
3. Recurrent aphthosis ulcer major (Sutton ulcer)
4. Recurrent herpetiform ulcerations
5. Behçet syndrome

Methods

A search on the major medical literature databases including PubMed, EMBASE and Cochrane Library was performed. The search was used the following search keys: “aphtha” AND “recurrent” OR “aphtha” AND “treatment.” Each article reporting relevant information on the pathogenesis as well as the management and treatment strategies was considered, and the main findings were included in the current review.

Diagnosis and Treatment

Recurrent aphthous stomatitis (RAS) [1], is a common oral disease characterized by multiple, small, round or oval mucosal ulcers with circumscribed margins, erythematous haloes, and yellow or gray floors that initially appear during childhood or adolescence. Many diseases [3-10] that affect the oral cavity can have similar clinical presentations, making correct diagnosis difficult and sometimes delaying therapy. Unfortunately, the etiology of RAS of is still unknown.

An RAS diagnosis is based on history and clinical findings [2]. The lesions can range from 1 to several rounded, shallow, painful ulcers and recur in bouts from a few days to few months. There are at least 5 forms of RAS, but the most common are minor (MiRAS), major (MaRAS), and herpetiformis ulcers (HU) [2]. Minor RAS is the most frequent, and it affects about 80% of patients with RAS. Aphthae are small, round or oval, usually with a gray-white pseudomembrane and an erythematous halo [1,2]. It usually occurs on non-keratinized surfaces, particularly the labial and buccal mucosa and the floor of the mouth, although it is uncommon on the gingiva, palate, or the back of the tongue [1,2]. Aphthae usually heal within 10-14 days [2,11,12]. MaRAS is a severe form of RAS that can be observed in about 10% of patients with RAS. Ulcers caused by MaRAS can be larger than 1 cm and often develop on the lips, soft palate and fauces. They persist for up to 6 weeks. MaRAS frequently has its onset after adolescence, is chronic, and lasts for up to 20 years or more [12,13]. Herpetiform ulcers affect about 1%-10% of patients with RAS. Up to 100 ulcers may be present at the same time, and while single lesions measure only few millimeters, they tend to coalesce to become large and irregular. HU are more frequent in women. Despite its name, no association with herpesvirus has been found [12,13].

Behçet disease (Adamantiades-Behçet disease [ABD]) [14,15] is a chronic and multisystemic inflammatory disease, characterized by oral aphthae at its onset, with the successive appearance of ocular, vascular, gastrointestinal, nervous and mucocutaneous lesions (Figure 1). ABD mainly affects young (20- to 40-year-old) males, but no age is spared [14,15]. The male: female ratio is reported to be from 3.1 to 1.1, with the same values being reported in the US and Europe [14,15]. The etiology of ABD is unknown but is most probably caused by an interplay of genetic and environmental factors [14-16].

Multiple oral aphthae and ulcers can be observed in association with several other clinical findings in many autoimmune diseases [3,17] or be induced by medications [18], genetic disease [19,20], and other complex inflammatory syndromes, such as mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome [21], Sweet syndrome [22-28], cyclic neutropenia [29-32], periodic fever with aphthae, pharyngitis and adenitis (sometimes termed PFAPA syndrome) [33–35], nutritional deficiencies [36,37], gluten-sensitive enteropathy (celiac disease), inflammatory

Figure 1. Recurrent aphthous stomatitis in a patient with Adamantiades-Behçet disease.
bowel disease, and immunodeficiencies [38,39] including HIV infection [40,41].

Recurrent ulcerative lesions of the oropharyngeal mucosa can be associated with many viral or bacterial infections [40,42-44]; therefore, it is important to exclude an infectious etiology before initiating immunosuppressive or an immunomodulatory therapy. AIDS is a progressive viral infection caused by HIV-1/2 viruses, with ulcerative oral manifestations in 8% of the cases [45]. Another cause of ulcerative lesions can be the herpes simplex virus infection (HSV-1/2) when oral and perioral ulcers are frequent symptoms. [43]. Recurrent oropharyngeal ulcers have been described in several infectious diseases as such as: secondary syphilis, tuberculosis, histoplasmosis, Lyme disease, COVID-19, Epstein-Barr virus, and cytomegalovirus infection [44]. The role of *Helicobacter pylori* as an etiology of ulcerative lesions of the oral cavity is still a matter of debate [42].

**Prevention and Therapy**

Several therapies, with variable degrees of supporting evidences, are available for the treatment of aphthous stomatitis [11]. Treatment for recurrent aphthous ulcers is aimed at mitigating symptoms, shortening the healing time, and is used as a prophylaxis against recurrence. Most of the treatments are prescribed without studies demonstrating therapeutic efficacy with respect to aphthous stomatitis. Topical regimens are considered to be the standard treatment in mild cases of RAS [2,11,46]. In more compromised cases, topical treatments are likewise very helpful in inducing lesion recovery, but they are often ineffective at prolonging disease-free intervals.

**Medical Care**

Topical therapies can include the following: corticosteroids, cyclosporine, retinoids, antimicrobials, anesthetics [47]. Topical corticosteroids are the first-line treatment, and they are used to reduce the local inflammation that induces ulceration. They include dexamethasone (0.5 mg/mL), triamcinolone (.0,1% gel), fluocinonide (0.05% gel) and clobetasol (0.05% gel). Clobetasol is a class 1 superpotent steroid, and is showing better results [2,46,47].

Immunomodulatory agents, include cyclosporine and retinoids. Cyclosporine has been prescribed as a systemic agent and a topical paste with variable reported efficacy, but it is now frequently used effectively as an oral rinse. Isotretinoin (0.1% gel) and tretinoin in an adhesive base (0.1%), and retinoic acid in an oral base (.05%) have been prescribed for the management of RAS [2,47,48]. Also, systemic isotretinoin has been reported to be an effective therapy for recurrent aphthosis [49,50].

Antimicrobials, including tetracycline, chlorhexidine gluconate, and diluted hydrogen peroxide have shown to reduce the duration and pain of oral aphthae [2,13].

Anesthetics such as topical lidocaine (2% viscous solution, gel, or spray) or benzocaine have been used to reduce the pain associated to RAS [13].

Occlusive and bioadherent agents, such as Gelclair, sulfacetamide, bismuth subsalicylate, and 2-octyl cyanoacrylate have been successfully used in RAS management, because they can generate a protective coating that shields exposed and overstimulated nerve endings [11].

**Systemic Agents**

Systemic therapy includes the following drugs: colchicine, pentoxifylline, steroids, dapsone, thalidomide, pidotimod [16,51,52]. Colchicine was reported to reduce the amount and duration of aphthae in up to 63% of patients with RAS. Treatment over 6 weeks, followed by long-term (years) therapy (1-2 mg daily) is recommended [53]. Combination therapy with colchicine and pentoxifylline, benzathine penicillin, immunosuppressants, or interferon-alpha is possible [52].

Systemic corticosteroids are prescribed as rescue therapy in patients with acute flares and in those who inadequately respond to therapy with colchicine and pentoxifylline. Oral prednisolone or its equivalents, at 10-30 mg daily for up to 1 month can be prescribed during a RAS exacerbation. Intravenous pulse therapy at 100 mg daily for 3 days results in quick improvement for severe cases of RAS [2].

Dapsone (100 mg daily) can be prescribed for oral and genital aphthae; however, rapid relapses can occur after discontinuation of therapy.

Thalidomide at standard (100-300 mg daily) or low (50 mg daily) dosing levels was shown to be effective within 7-10 weeks following administration [54].

In a recent study a new therapeutic high dosage of pidotimod in children with PFAPA (including RAS) showed promising results. Pidotimod is an immunomodulatory agent that increases antigen presentation and promotes adaptive Th1-mediated immunity [55].

**Low Laser Therapy**

Four types of lasers have been described in aphthae treatment: CO2, Nd:YAG, diode, and GaAlAs [56]. The main goal of treatment is to decrease pain, healing time, number, and size of ulcers. The main advantage of laser therapy over other treatments is that it can be used for all the causes of the disease without systemic side effects.

**Adamantiades-Behçet Disease**

Systemic glucocorticoids are effective for most manifestations of ABD. They are administered at doses of 50-60 mg of prednisone per day, or the equivalent, with a tapering scheme [14,15]. Therefore, other therapies are often used instead of, or as an adjunct to systemic glucocorticoid therapy, such as
cyclosporine, colchicine, cyclophosphamide, dapsone, infliximab, interferon alfa-2a, and thalidomide [14-16,49,52]. When mucocutaneous lesions are the main concern in patients with mild-to-moderate aphthosis, the application of topical steroids may obviate the need for systemic therapy. Mild aphthosis may also benefit from the applications of topical sucralfate, topical tetracycline, or a course of zinc sulfate (100 mg orally twice daily) or azithromycin (500 mg orally 3 times weekly) [51]. Azathioprine also proved to be effective in a randomized clinical trial for the prevention of both oral and genital ulcers. In patients with more severe, recalcitrant mucocutaneous lesions, dapsone (100 mg daily) and thalidomide (100 mg daily) are considered particularly effective.

Conclusions

Recurrent aphthous stomatitis is a common disorder affecting the oral cavity with 3 main presentations: minor, major or herpetiformis ulcers. An RAS diagnosis is often based on history and clinical findings. Recurrent oral ulcerative lesions are rarely associated with several complex inflammatory syndromes and to viral or bacterial infections. Therefore, it is always important to exclude the presence of a systemic or an infectious disease before starting an immunosuppressive or an immunomodulatory therapy.

References

1. Giannetti L, Murri Dello Diago A, Lo Muzio L. Recurrent aphthous stomatitis. Minerva Stomatol. 2018;67(3):125–128. DOI: 10.23736/S0026-4970.18.04137-7. PMID: 29332375.
2. Edgar NR, Saleh D, Miller RA. Recurrent aphthous stomatitis: a review. J Clin Aesthetic Dermatol. 2017;10(3):26–36.
3. Giannetti L, Generali L, Bertoldi C. Oral pemphigus. G Ital Dermatol Venereol. 2018;153(3):383–388. DOI: 10.23736/S0392-0488.18.05887-X. PMID: 29512980.
4. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. JAAD Case Rep. 2020;6(1):116–121. DOI: 10.1016/j.jdcr.2019.05.009. PMID: 31440559.
5. Castori M, Madonna S, Giannetti L, et al. Novel CTSC mutations in a patient with Papillon-Lefèvre syndrome with recurrent pyoderma and minimal oral and palmoplantar involvement.

Br J Dermatol. 2009;160(4):881–883. DOI: 10.1111/j.1365-2133.2008.08878.x. PMID: 18945301.
6. Giannetti L, Apponi R, Dello Diago AM, Jafferany M, Goldust M, Sadoughifar R. Papillon-Lefèvre syndrome: Oral aspects and treatment. Dermatol Ther. 2020;33(3):e13336. DOI: 10.1111/dth.13336. PMID: 32221110.
7. Altenburg A, Zouboulis CC. Current concepts in the treatment of recurrent aphthous stomatitis. Skin Ther Lett. 2008;13(7):1–4. PMID: 18839042.
8. Yasui K, Kurata T, Yashiro M, Tsuge M, Ohtsuki S, Morishima T. The effect of ascorbate on minor recurrent aphthous stomatitis. Acta Paediatr. 1992;100(9):442–445. DOI: 10.1111/j.1651-2227.2009.01628.x. PMID: 20003102.
9. Montgomery-Cranny JA, Wallace A, Rogers HJ, Hughes SC, Hegarty AM, Zaitoun H. Management of recurrent aphthous stomatitis in children. Dent Update. 2015;42(6):564–566, 569–572. DOI: 10.12968/denu.2015.42.6.564. PMID: 26506812.
10. Bulur I, Onder M. Behçet disease: new aspects. Clin Dermatol. 2017;35(5):421–434. DOI: 10.1016/j.clindermatol.2017.06.004. PMID: 28916023.
11. Giannetti L, Murri Dello Diago A, Lo Muzio L. Behçet’s disease: minireview with emphasis on oral aspects. Minerva Stomatol. 2018;67(6):246–249. DOI: 10.23736/S0026-4970.18.04135-3.
12. Arida A, Fragiadaki K, Giavi E, Sifakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70. DOI: 10.1016/j.semarthrit.2010.09.002. PMID: 21168186.
13. Mandel VD, Farnetani F, Vascieri C, et al. Pemphigus with features of both vulgaris and foliaceus variants localized to the nose. J Dermatol. 2016;43(8):940–943. DOI: 10.1111/1346-8138.13314. PMID: 26945696.
14. Celentano A, Tovar S, Yap T, Adamo D, Aria M, Mignogna MD. Oral erythema multiforme: trends and clinical findings of a large retrospective European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(6):707–716. DOI: 10.1016/j.ooos.2015.08.010. PMID: 26455287.
15. Ponti G, Tomasi A, Manfredini M, Pellacani G. Oral mucosal stigmata in hereditary-cancer syndromes: From germline mutations to distinctive clinical phenotypes and tailored therapies. Gene. 2016;582(1):23–32. DOI: 10.1016/j.gene.2016.01.053. PMID: 26850131.
16. Ponti G, Meschieri A, Pollio A, et al. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy. J Oral Pathol Med. 2015;44(7):552–557. DOI: 10.1111/opd.12256. PMID: 25213213.
17. Delke I, Veridiano NP, Tancer ML, Gomez L, Diamond I. Sweet syndrome and recurrent valve prosthesis dehiscence in MAGIC syndrome. J Rheumatol. 1993;20(2):397–398.
18. Delke I, Veridiano NP, Tancer ML, Gomez L, Diamond I. Sweet syndrome with involvement of the female genital tract. Obstet Gynecol. 1981;58(3):394–396.
19. Driban NE, Alvarez MA. Oral manifestations of Sweet’s syndrome. Dermatol. 1984;169(2):102–103. DOI: 10.1159/000249579.
20. Mizoguchi M, Matsuji K, Mochizuki M, et al. Human leukocyte antigen in Sweet’s syndrome and its relationship to Behçet’s disease. Arch Dermatol. 1988;124(7):1069–1073. DOI: 10.1001/archderm.1988.01670070057019. PMID: 3389850.
25. von den Driesch P, Gomez RS, Kiesewetter F, Hornstein OP. Sweet's syndrome: clinical spectrum and associated conditions. Catiss. 1989;44(3):193–200.
26. Bruyn GA, Missier ET, Toostra J, Bijlsma JW. Sweet's syndrome. Neth J Med. 1990;36(1–2):62–68.
27. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):533–56. DOI: 10.1016/S0190-9262(94)00125-2.
28. Femiano F, Gombos F, Scully C. Sweet's syndrome: recurrent oral ulceration, pyrexia, thrombophlebitis, and cutaneous lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):324–327. DOI: 10.1067/moe.2003.4. PMID: 12627104.
29. Lange RD, Jones JB. Cyclic neutropenia. Review of clinical manifestations and management. Am J Pediatr Hematol Oncol. 1981;3(4):363–367.
30. Scully C, MacFadyen E, Campbell A. Oral manifestations in cyclic neutropenia. Br J Oral Surg. 1982;20(2):96–101. DOI: 10.1016/0007-117X(82)90015-4.
31. Sucker C, Djawari J. [Recent episodes of ulcerative gingivostomatitis associated with cyclic neutropenia]. Hautarzt. 1999;50(7):503–506. DOI: 10.1007/s001050050042.
32. Lubitz PA, Dower N, Krol AL. Cyclic neutropenia: an unusual disorder of granulopoiesis effectively treated with recombinant granulocyte colony-stimulating factor. Pediatr Blood Cancer. 2001;18(5):426–432. DOI: 10.1046/j.1525-1470.2001.01974.x. PMID: 11736791.
33. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987;110(1):43–6.
34. Feder HM. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis: a clinical review of a new syndrome. Curr Opin Pediatr. 2000;12(3):253–256. DOI: 10.1097/00002957-200006000-00014. PMID: 10836162.
35. Kawashima H, Nishimata S, Shimizu T, Kashiwagi Y, Takekuma K, Hoshika A. Highly suspected case of FAPA (periodic fever, aphthous stomatitis, pyoderma, and bullous diseases). Selective review of the literature. Head Neck Pathol. 2009;3 Suppl 1:S194-196. DOI: 10.10111/j.1610-0825.2009.00038.x. PMID: 19456687.
36. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol. 1994;77(6):555–571. DOI: 10.1016/0190-9262(94)90312-3.
37. Porter SR, Scully C, Luker J. Complications of dental surgery in persons with HIV disease. Oral Surg Oral Med Oral Pathol. 1993;75(2):165–167. DOI: 10.1016/0190-9220(93)90087-K.
38. Scully C, Porter SR. Oral mucosal disease: a decade of new entities, aetiologies and associations. Int Dent J. 1994;44(1):33–43. PMID: 8021031.
39. MacPhail LA, Greenspan JS. Oral ulceration in HIV infection: investigation and pathogenesis. Oral Dis. 1997;3 Suppl 1:S190-193. DOI: 10.1111/j.1601-0825.1997.tb00358.x. PMID: 9456687.
40. Zakrzewska JM, Robinson P, Williams IG. Severe oral ulceration in patients with HIV infection: a case series. Oral Dis. 1997;3 Suppl 1:S194-196. DOI: 10.1111/j.1601-0825.1997.tb00359.x. PMID: 9456688.
41. Li L, Gu H, Zhang G. Association between recurrent aphthous stomatitis and Helicobacter pylori infection: a meta-analysis. Clin Oral Investig. 2014;18(6):1553–1560. DOI: 10.1007/s00784-014-1230-5. PMID: 24682540.
42. Arduini PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis. 2006;12(3):254–270. DOI: 10.1111/j.1601-0825.2006.01202.x. PMID: 16700734.
43. Fitzpatrick SG, Cohen DM, Clark AN. Ulcerated Lesions of the oral mucosa: clinical and histologic review. Head Neck Pathol. 2019;13(1):91–102. DOI: 10.1007/s12105-018-0981-8. PMID: 30701449.
44. Patil N, Chaurasia VR, Babaji P, Ramesh D, Jhamb K, Sharma AM. The effect of highly active antiretroviral therapy on the prevalence of oral manifestation in human immunodeficiency virus-infected patients in Karnataka, India. Eur J Dent. 2015;9(1):47–52.
45. Giannetti L, Murri Dello Diago A, Lo Muzio L. Recurrent aphthous stomatitis. Minerva Stomatol. 2018;67(3):125–8. DOI: 10.23736/so026-4970.18.04137-7. PMID: 29332375.
46. Dallemandi D, Zotti F, Lafranchi L, Migliorati M, Isola G, Bonetti S, et al. Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study. BMC Oral Health. 2019;19(1):153. DOI: 10.1186/s12903-019-0850-1. PMID: 31311529.
47. Carl W, Havens J. The cancer patient with severe mucositis. Curr Rev Pain. 2000;4(3):197–202. DOI: 10.1016/S1191-9600-00079-2.
48. Sharque KE, Helmi RMA, Noami AA, Al-Hayani RK, Kadhom MAA. The therapeutic role of isotretinoin in the management of Behcet’s disease: a single-blinded, controlled therapeutic study. J Drugs Dermatol. 2013;12(4):e68-73.
49. Elad S, Epstein JB, von Buldzensöwen I, Drucker S, Tzach R, Yarom N. Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents. Expert Opin Emerg Drugs. 2011;16(1):183–202. DOI: 10.1517/14728214.2011.528390. PMID: 21244328.
50. Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behcet’s disease. J Oral Pathol Med.2003;34(1):13–16. DOI: 10.1111/j.1600-0714.2004.00265.x. PMID: 13610401.
51. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon α-2a in the treatment of Behcet’s disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471. DOI: 10.1001/archderm.138.4.467. PMID: 11939808.
52. Dasegb B, Kornreich D, McGUinn K, Okon L, Brownell DL. Colchicine: an ancient drug with novel applications. Arch Dermatol. 2013;149(6):734–737. DOI: 10.1001/archderm.138.4.467. PMID: 11939808.
53. Harte MC, Saunsbury TA, Hodgson TA. Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(4):398–401. DOI: 10.1016/j畲sormed.2020.06.009. PMID: 32622799.
54. Radulescu M. The pharmacologic management of common lesions of the oral cavity. Dent Clin North Am. 2016;60(2):407–420. DOI: 10.1016/j.dclinam.2015.12.003. PMID: 27040292.
55. Akerzoul N, Chbicheb S. Low laser therapy as an effective treatment of recurrent aphthous ulcers: a clinical case reporting two locations. Pan Afr Med J. 2018;30:205. PMID: 30574224.